Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06930859 2026-05-22

ELEGANCE

Recruiting

2,766 enrolled

Breast

Breast Neoplasms

NCT07174336 2026-05-22

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Phase 3 Recruiting

920 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07492641 2026-05-22

KANDELA-302

Phase 3 Recruiting

1,056 enrolled

Breast

HR+/HER2- Breast Cancer

NCT06760637 2026-05-19

FourLight-3

Phase 3 Active not recruiting

1,035 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

1,180 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

80 enrolled

Breast

Breast Neoplasms

NCT06380751 2026-05-15

EvoPAR-BR01

Phase 3 Recruiting

500 enrolled

Breast

Advanced Breast Cancer

NCT07085767 2026-05-15

OPERA-02

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT05296746 2026-05-14

RIBOLARIS

Phase 2 Active not recruiting

1,100 enrolled

Breast

Breast Neoplasms

NCT05827081 2026-05-14

Adjuvant WIDER

Phase 3 Recruiting

1,400 enrolled

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT06377852 2026-05-13

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Phase 3 Recruiting

500 enrolled

Breast

Breast Neoplasms

NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Phase 3 Not yet recruiting

1,978 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT04055493 2026-05-11

ADAPTcycle

Phase 3 Active not recruiting

1,684 enrolled

Breast

Breast Neoplasms

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05319873 2026-05-11

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Active not recruiting

18 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT06188520 2026-05-11

CYCAD-1

Phase 1/2 Recruiting

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT06830720 2026-05-08

CAROLEEN

Recruiting

3,250 enrolled

Breast

Breast Neoplasms

NCT06075758 2026-05-06

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Completed

175 enrolled

Breast

Breast Neoplasms

NCT06065748 2026-05-05

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Phase 3 Recruiting

1,050 enrolled

Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06905301 2026-05-05

IMPULSE

Recruiting

240 enrolled

Breast

Breast Neoplasms

Clinical Trials

CAPItello-292

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

SELECT

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NoLEEta

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

PIKALO-1

ELEGANCE

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

KANDELA-302

FourLight-3

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

EvoPAR-BR01

OPERA-02

RIBOLARIS

Adjuvant WIDER

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

ADAPTcycle

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

CYCAD-1

CAROLEEN

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

IMPULSE